Cargando…

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases

Receptor activator of NF-kB (RANK) pathway regulates bone remodeling and is involved in breast cancer (BC) progression. Genetic polymorphisms affecting RANK-ligand (RANKL) and osteoprotegerin (OPG) have been previously associated with BC risk and bone metastasis (BM)-free survival, respectively. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Arlindo, Alho, Irina, Vendrell, Inês, Melo, Marta, Brás, Raquel, Costa, Ana Lúcia, Sousa, Ana Rita, Mansinho, André, Abreu, Catarina, Pulido, Catarina, Macedo, Daniela, Pacheco, Teresa, Correia, Lurdes, Costa, Luis, Casimiro, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173066/
https://www.ncbi.nlm.nih.gov/pubmed/27191503
http://dx.doi.org/10.18632/oncotarget.9356
_version_ 1782484255279939584
author Ferreira, Arlindo
Alho, Irina
Vendrell, Inês
Melo, Marta
Brás, Raquel
Costa, Ana Lúcia
Sousa, Ana Rita
Mansinho, André
Abreu, Catarina
Pulido, Catarina
Macedo, Daniela
Pacheco, Teresa
Correia, Lurdes
Costa, Luis
Casimiro, Sandra
author_facet Ferreira, Arlindo
Alho, Irina
Vendrell, Inês
Melo, Marta
Brás, Raquel
Costa, Ana Lúcia
Sousa, Ana Rita
Mansinho, André
Abreu, Catarina
Pulido, Catarina
Macedo, Daniela
Pacheco, Teresa
Correia, Lurdes
Costa, Luis
Casimiro, Sandra
author_sort Ferreira, Arlindo
collection PubMed
description Receptor activator of NF-kB (RANK) pathway regulates bone remodeling and is involved in breast cancer (BC) progression. Genetic polymorphisms affecting RANK-ligand (RANKL) and osteoprotegerin (OPG) have been previously associated with BC risk and bone metastasis (BM)-free survival, respectively. In this study we conducted a retrospective analysis of the association of five missense RANK SNPs with clinical characteristics and outcomes in BC patients with BM. SNP rs34945627 had an allelic frequency of 12.5% in BC patients, compared to 1.2% in the control group (P = 0.005). SNP rs34945627 was not associated with any clinicopathological characteristics, but patients presenting SNP rs34945627 had decreased disease-free survival (DFS) (log-rank P = 0.039, adjusted HR 2.29, 95% CI 1.04–5.08, P = 0.041), and overall survival (OS) (log-rank P = 0.019, adjusted HR 4.32, 95% CI 1.55–12.04, P = 0.005). No differences were observed regarding bone disease-free survival (log-rank P = 0.190, adjusted HR 1.68, 95% CI 0.78–3.66, P = 0.187), time to first skeletal-related event (log-rank P = 0.753, adjusted HR 1.28, 95% CI 1.42–3.84; P = 0.665), or time to bone progression (log-rank P = 0.618, adjusted HR 0.511, 95% CI 0.17–1.51; P = 0.233). Our analysis shows that RANK SNP rs34945627 has a high allelic frequency in patients with BC and BM, and is associated with decreased DFS and OS.
format Online
Article
Text
id pubmed-5173066
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-51730662016-12-23 The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases Ferreira, Arlindo Alho, Irina Vendrell, Inês Melo, Marta Brás, Raquel Costa, Ana Lúcia Sousa, Ana Rita Mansinho, André Abreu, Catarina Pulido, Catarina Macedo, Daniela Pacheco, Teresa Correia, Lurdes Costa, Luis Casimiro, Sandra Oncotarget Research Paper Receptor activator of NF-kB (RANK) pathway regulates bone remodeling and is involved in breast cancer (BC) progression. Genetic polymorphisms affecting RANK-ligand (RANKL) and osteoprotegerin (OPG) have been previously associated with BC risk and bone metastasis (BM)-free survival, respectively. In this study we conducted a retrospective analysis of the association of five missense RANK SNPs with clinical characteristics and outcomes in BC patients with BM. SNP rs34945627 had an allelic frequency of 12.5% in BC patients, compared to 1.2% in the control group (P = 0.005). SNP rs34945627 was not associated with any clinicopathological characteristics, but patients presenting SNP rs34945627 had decreased disease-free survival (DFS) (log-rank P = 0.039, adjusted HR 2.29, 95% CI 1.04–5.08, P = 0.041), and overall survival (OS) (log-rank P = 0.019, adjusted HR 4.32, 95% CI 1.55–12.04, P = 0.005). No differences were observed regarding bone disease-free survival (log-rank P = 0.190, adjusted HR 1.68, 95% CI 0.78–3.66, P = 0.187), time to first skeletal-related event (log-rank P = 0.753, adjusted HR 1.28, 95% CI 1.42–3.84; P = 0.665), or time to bone progression (log-rank P = 0.618, adjusted HR 0.511, 95% CI 0.17–1.51; P = 0.233). Our analysis shows that RANK SNP rs34945627 has a high allelic frequency in patients with BC and BM, and is associated with decreased DFS and OS. Impact Journals LLC 2016-05-13 /pmc/articles/PMC5173066/ /pubmed/27191503 http://dx.doi.org/10.18632/oncotarget.9356 Text en Copyright: © 2016 Ferreira et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ferreira, Arlindo
Alho, Irina
Vendrell, Inês
Melo, Marta
Brás, Raquel
Costa, Ana Lúcia
Sousa, Ana Rita
Mansinho, André
Abreu, Catarina
Pulido, Catarina
Macedo, Daniela
Pacheco, Teresa
Correia, Lurdes
Costa, Luis
Casimiro, Sandra
The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
title The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
title_full The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
title_fullStr The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
title_full_unstemmed The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
title_short The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
title_sort prognostic role of rank snp rs34945627 in breast cancer patients with bone metastases
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173066/
https://www.ncbi.nlm.nih.gov/pubmed/27191503
http://dx.doi.org/10.18632/oncotarget.9356
work_keys_str_mv AT ferreiraarlindo theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT alhoirina theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT vendrellines theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT melomarta theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT brasraquel theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT costaanalucia theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT sousaanarita theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT mansinhoandre theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT abreucatarina theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT pulidocatarina theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT macedodaniela theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT pachecoteresa theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT correialurdes theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT costaluis theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT casimirosandra theprognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT ferreiraarlindo prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT alhoirina prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT vendrellines prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT melomarta prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT brasraquel prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT costaanalucia prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT sousaanarita prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT mansinhoandre prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT abreucatarina prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT pulidocatarina prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT macedodaniela prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT pachecoteresa prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT correialurdes prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT costaluis prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases
AT casimirosandra prognosticroleofranksnprs34945627inbreastcancerpatientswithbonemetastases